Haemonetics (NYSE:HAE) Updates FY 2025 Earnings Guidance

Haemonetics (NYSE:HAE) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 4.500-4.700 for the period, compared to the consensus earnings per share estimate of 4.590. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on HAE shares. Barrington Research restated an “outperform” rating and set a $108.00 price target on shares of Haemonetics in a report on Wednesday, December 4th. JPMorgan Chase & Co. initiated coverage on Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and set a $112.00 price target on shares of Haemonetics in a report on Tuesday, December 3rd. Finally, Raymond James raised shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target on the stock in a research report on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $108.78.

Haemonetics Stock Performance

NYSE:HAE opened at $71.26 on Thursday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. The firm’s 50-day moving average is $77.77 and its 200-day moving average is $78.79. Haemonetics has a 52-week low of $65.73 and a 52-week high of $97.97. The company has a market cap of $3.58 billion, a price-to-earnings ratio of 29.57, a PEG ratio of 1.07 and a beta of 0.39.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.03. The company had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. Haemonetics’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.99 EPS. Equities research analysts anticipate that Haemonetics will post 4.59 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.